Rein Therapeutics publishes first-in-human LTI-03 idiopathic pulmonary fibrosis data in Nature Communications
RNTX•Study findings in idiopathic pulmonary fibrosis
The small, randomized, placebo-controlled study in idiopathic pulmonary fibrosis showed LTI-03 was safe and well-tolerated over 14 days.
Findings indicated reductions in markers tied to lung scarring and inflammation, supporting the ongoing Phase 2 RENEW trial.
Nature Communications publication of first-in-human data
Rein Therapeutics reported peer-reviewed publication of first-in-human LTI-03 data in Nature Communications; results were previously presented as a preprint in November 2025.
